Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Inceptua Group.

    Client Virtual Booth

    INCEPTUA GROUP

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Inceptua Group
    Luxembourg Flag
    Country
    Country
    Luxembourg
    Address
    Address
    Inceptua S.A. 2 place de Paris 2314 Luxembourg
    Telephone
    Telephone
    +352 39 87 45 00
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.inceptua.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/inceptua-group/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Elevar Therapeutics Inc. Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea® (Paclitaxel Micellar) in Europe

    Details:

    Under the terms of the agreement, Inceptua will have exclusive rights to distribute and commercialize Apealea in Europe. These rights do not extend to the Nordic countries (Denmark, Finland, Norway, Sweden, Iceland).


    Lead Product(s): Paclitaxel

    Therapeutic Area: Oncology Product Name: Apealea

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Elevar Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement December 28, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Oxurion and Inceptua Group enter global license agreement for the commercialization of JETREA®

    Details:

    The Agreement with Inceptua will allow Oxurion to focus fully on further advancing its promising next-generation therapeutic pipeline of non-VEGF products for the treatment of diabetic eye disease.


    Lead Product(s): Ocriplasmin

    Therapeutic Area: Ophthalmology Product Name: Undisclosed

    Highest Development Status: ApprovedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Oxurion

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement March 13, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search